From Target List to Validated AOC Panel

Building a multiplexed antibody oligonucleotide conjugate panel is rarely straightforward. A target list may look clear on paper, but moving from marker selection to a panel that performs reliably in tissue takes careful testing at every stage. That is the value of the 2025 STAR Protocols paper by Gupta, Abraham, Goncalves, Miller, and del Rincón. It focuses on the real work of panel development and sets out a practical workflow for taking DNA barcoded antibodies from early selection through to multiplexed imaging.

This is a useful paper because it does not treat panel design as a simple matter of picking antibodies and running a final assay. Instead, it shows that each stage matters. Antibody choice, conjugation, validation, and staining conditions all need to be considered in sequence if the final panel is going to perform as intended.

Why Panel Development Is Such a Demanding Process

Multiplex immunofluorescence offers the ability to study many markers within the same sample, which makes it highly valuable for complex biological questions. But that flexibility comes with a challenge. A panel that works well is the result of repeated testing and refinement, not a single optimization step.

This is particularly important when custom panel design is required. Commercial panels may suit certain workflows, but they are often limited to a specific method and may not transfer easily to a different protocol, tissue type, or research question. For teams developing their own panels, there is a significant amount of work between identifying the right targets and producing reliable imaging data.

That is what makes this protocol so helpful. It sets out the path clearly and shows that panel building is a structured process.

For readers looking for broader context on AOCs in multiplexed workflows, AbOliGo's knowledge hub includes useful material on single cell and multi-omics applications.

What the Protocol Covers

The workflow described in the paper includes several key stages that support panel development in a logical order. These include initial antibody selection, antibody screening, single-plex validation, fluorophore selection based on antigen abundance, and systematic testing before moving into full multiplex runs.

Seen together, these steps make an important point. Panel design is not only about identifying the right biology. It is also about reducing uncertainty at each stage before introducing the added complexity of a multiplex format.

A useful companion piece within the AbOliGo Knowledge Hub is Scientific Techniques Using Antibody Oligonucleotide Conjugates, which gives broader background on how AOCs are used across different assay formats.

Why Antibody Performance Has to Be Reassessed After Conjugation

One of the most important messages in the paper is that an antibody validated for standard immunofluorescence may not behave the same way once it has been conjugated to an oligonucleotide. This is a practical point with real consequences for panel development.

The paper highlights that staining time, temperature, and concentration may all need to be re-optimized after conjugation. In other words, a successful antibody does not automatically become a successful AOC, and a collection of successful AOCs does not automatically become a successful multiplex panel.

That distinction is easy to overlook, but it is central to the whole workflow. It explains why panel development can be so time intensive and why proper validation remains essential.

Readers working through similar challenges may also find AbOliGo's Bioconjugation Optimization resources useful, especially the material focused on reducing non-specific binding.

How the AOCs Were Prepared in This Workflow

The protocol uses a maleimide-thiol conjugation approach. In this process, antibodies are reduced to expose thiol groups and then covalently linked to unique oligonucleotide barcodes.

The paper also notes an important requirement for this chemistry. Antibodies must be carrier free, with no BSA or glycerol present, for the conjugation to proceed successfully. That is not a minor detail. It directly affects which antibody preparations can be used and can limit the starting materials available for panel development.

For readers interested in the underlying chemistry, AbOliGo's Conjugation Chemistry and Methods resources offer further background on antibody oligonucleotide conjugation strategies.

Why Conjugation Quality Must Be Checked Early

The paper reports that conjugation was validated using an SDS-PAGE gel shift assay. This was used to confirm the expected increase in molecular weight after oligonucleotide barcode attachment.

This is an important checkpoint in the workflow. Before committing to downstream testing, the protocol verifies that the antibody has actually been modified as intended. That kind of early confirmation helps prevent wasted effort later in the process.

A closely related resource in the AbOliGo Knowledge Hub is the Guide to Using SDS-PAGE to Characterize Antibody Oligonucleotide Conjugates, found within the analytical characterization and quality control content.

What This Paper Makes Clear

The strength of this protocol lies in its realism. It does not present multiplex panel development as a shortcut from target list to finished assay. Instead, it makes clear that success depends on methodical work at each stage.

That is especially relevant for laboratories building custom imaging panels. The challenge is not simply deciding which markers to include. It is ensuring that each antibody remains functional after conjugation and performs properly within the final imaging workflow.

This is why practical guidance of this kind matters. As the use of spatial and multiplexed proteomics continues to grow, the need for reliable, ready-to-conjugate reagents and clear validation workflows will only become more important.

For more on related imaging approaches, AbOliGo's Advanced Imaging and Multiplexing resources include material on cyclic immunofluorescence with DNA barcoded antibodies.

Reference